Abstract
Prior studies have revealed that the presence of increasing number of polyclonal plasma cells (pPCs) in the bone marrow (BM) are associated with better outcomes in newly diagnosed multiple myeloma (MM) patients. This effect has not been studied in patients with MM at the time of disease relapse. We determined the prognostic value of depletion of pPCs in the BM by 7-color multiparameter flow cytometry in a series of 174 relapsing MM patients. The time to next therapy (TTNT) in those with <5% pPCs was 9.4 months versus 13.9 months in those with ≥5% pPCs (P =.0091). The median overall survival (OS) in those with <5% pPCs was 21.4 months, while the median OS was not reached in those patients with ≥5% pPCs (P =.019). Of the 109 patients with standard risk cytogenetics, the median OS of those with <5% pPCs was 28.4 months, while the median OS was not reached in those with ≥5% pPCs (P =.033). As such, <5% pPCs in the BM appears to have prognostic utility in identifying a subset of relapsing MM patients, even with standard-risk cytogenetics, who have a particularly adverse outcome.
| Original language | English (US) |
|---|---|
| Pages (from-to) | E507-E512 |
| Journal | American Journal of Hematology |
| Volume | 92 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 1 2017 |
Fingerprint
ASJC Scopus subject areas
- Hematology
Cite this
The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. / Ghosh, Toshi; Gonsalves, Wilson; Jevremovic, Dragan; Dispenzieri, Angela; Dingli, David M; Timm, Michael M.; Morice, William G.; Kapoor, Prashant; Kourelis, Taxiarchis; Lacy, Martha; Hayman, Suzanne R.; Buadi, Francis K.; Leung, Nelson; Go, Ronald S.; Lin, Yi; Russell, Stephen J; Lust, John A.; Zeldenrust, Steven R.; Warsame, Rahma; Hwa, Yi L.; Kyle, Robert A.; Gertz, Morie; Rajkumar, S Vincent; Kumar, Shaji K.
In: American Journal of Hematology, Vol. 92, No. 9, 01.09.2017, p. E507-E512.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma
AU - Ghosh, Toshi
AU - Gonsalves, Wilson
AU - Jevremovic, Dragan
AU - Dispenzieri, Angela
AU - Dingli, David M
AU - Timm, Michael M.
AU - Morice, William G.
AU - Kapoor, Prashant
AU - Kourelis, Taxiarchis
AU - Lacy, Martha
AU - Hayman, Suzanne R.
AU - Buadi, Francis K.
AU - Leung, Nelson
AU - Go, Ronald S.
AU - Lin, Yi
AU - Russell, Stephen J
AU - Lust, John A.
AU - Zeldenrust, Steven R.
AU - Warsame, Rahma
AU - Hwa, Yi L.
AU - Kyle, Robert A.
AU - Gertz, Morie
AU - Rajkumar, S Vincent
AU - Kumar, Shaji K
PY - 2017/9/1
Y1 - 2017/9/1
N2 - Prior studies have revealed that the presence of increasing number of polyclonal plasma cells (pPCs) in the bone marrow (BM) are associated with better outcomes in newly diagnosed multiple myeloma (MM) patients. This effect has not been studied in patients with MM at the time of disease relapse. We determined the prognostic value of depletion of pPCs in the BM by 7-color multiparameter flow cytometry in a series of 174 relapsing MM patients. The time to next therapy (TTNT) in those with <5% pPCs was 9.4 months versus 13.9 months in those with ≥5% pPCs (P =.0091). The median overall survival (OS) in those with <5% pPCs was 21.4 months, while the median OS was not reached in those patients with ≥5% pPCs (P =.019). Of the 109 patients with standard risk cytogenetics, the median OS of those with <5% pPCs was 28.4 months, while the median OS was not reached in those with ≥5% pPCs (P =.033). As such, <5% pPCs in the BM appears to have prognostic utility in identifying a subset of relapsing MM patients, even with standard-risk cytogenetics, who have a particularly adverse outcome.
AB - Prior studies have revealed that the presence of increasing number of polyclonal plasma cells (pPCs) in the bone marrow (BM) are associated with better outcomes in newly diagnosed multiple myeloma (MM) patients. This effect has not been studied in patients with MM at the time of disease relapse. We determined the prognostic value of depletion of pPCs in the BM by 7-color multiparameter flow cytometry in a series of 174 relapsing MM patients. The time to next therapy (TTNT) in those with <5% pPCs was 9.4 months versus 13.9 months in those with ≥5% pPCs (P =.0091). The median overall survival (OS) in those with <5% pPCs was 21.4 months, while the median OS was not reached in those patients with ≥5% pPCs (P =.019). Of the 109 patients with standard risk cytogenetics, the median OS of those with <5% pPCs was 28.4 months, while the median OS was not reached in those with ≥5% pPCs (P =.033). As such, <5% pPCs in the BM appears to have prognostic utility in identifying a subset of relapsing MM patients, even with standard-risk cytogenetics, who have a particularly adverse outcome.
UR - http://www.scopus.com/inward/record.url?scp=85025079261&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85025079261&partnerID=8YFLogxK
U2 - 10.1002/ajh.24807
DO - 10.1002/ajh.24807
M3 - Article
C2 - 28568244
AN - SCOPUS:85025079261
VL - 92
SP - E507-E512
JO - American Journal of Hematology
JF - American Journal of Hematology
SN - 0361-8609
IS - 9
ER -